First-in-man use of a cardiovascular cell-derived secretome in heart failure. Case report.

ABSTRACT:

Background

There is increased evidence that the effects of stem cells can mostly be duplicated by administration of their secretome which might streamline the translation towards the clinics.

Methods

The 12-patient SECRET-HF phase 1 trial has thus been designed to determine the feasibility and safety of repeated intravenous injections of the extracellular vesicle (EV)-enriched secretome of cardiovascular progenitor cells differentiated from pluripotent stem cells in severely symptomatic patients with drug-refractory left ventricular (LV) dysfunction secondary to non-ischemic dilated cardiomyopathy. Here we report the case of the first treated patient (baseline NYHA class III; LV Ejection Fraction:25%) in whom a dose of 20 × 10⁹ particles/kg was intravenously infus

SUBMITTER: Menasche P 

PROVIDER: S-EPMC11096705 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature